 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Foundations of Tumor Mutational Profiling

Introduction to Tumor Mutational Profiling and Precision Oncology

Specimen Types, Testing Methods, and Reporting Considerations

Microsatellite Instability and Mismatch Repair Deficiency

Microsatellites and the DNA Mismatch Repair Pathway

Biological Relationship Between dMMR and MSI

Clinical Testing and Interpretation of MSI and dMMR

Tumor Mutational Burden

Definition and Calculation of Tumor Mutational Burden

Clinical Relevance and Limitations of TMB

Homologous Recombination Deficiency

Homologous Recombination and DNA Double-Strand Break Repair

HRD Testing and Therapeutic Implications

Integrating Biomarker Results in Clinical Practice

Comparing MSI, dMMR, TMB, and HRD

Responsible Interpretation and Communication of Biomarker Findings

Quiz

Question 1: Which description best distinguishes dMMR from MSI?

Question 2: What is the primary normal function of the DNA mismatch repair pathway?

Question 3: How is tumor mutational burden commonly reported?

Question 4: Which DNA repair process is impaired in homologous recombination deficiency?

Question 5: Why should biomarker results be interpreted in the context of tumor type and the specific testing assay?

Survey and Feedback

Course Feedback: How effectively did this course improve your understanding of tumor mutational profiling and biomarkers?

Welcome to "Tumor Mutational Profiling and Biomarkers in Personalized Cancer Therapy," a comprehensive online course designed to demystify the molecular foundations of modern precision oncology. As cancer treatment rapidly evolves, understanding the genetic and molecular drivers of tumors is no longer optional—it is essential for delivering targeted, effective patient care.

Welcome to "Tumor Mutational Profiling and Biomarkers in Personalized Cancer Therapy," a comprehensive online course designed to demystify the molecular foundations of modern precision oncology. As cancer treatment rapidly evolves, understanding the genetic and molecular drivers of tumors is no longer optional—it is essential for delivering targeted, effective patient care. This course provides an in-depth exploration of how tumor mutational profiling supports personalized cancer treatment decisions. You will dive into the core biomarkers shaping today's therapeutic landscape, including Microsatellite Instability (MSI), Mismatch Repair Deficiency (dMMR), Tumor Mutational Burden (TMB), and Homologous Recombination Deficiency (HRD). Through expertly crafted modules, you will learn to differentiate between somatic alterations and inherited germline variants, understand the biological processes behind DNA repair pathways, and navigate the complexities of specimen types and testing methods like Next-Generation Sequencing (NGS). Beyond the science, this course emphasizes practical clinical application. You will discover how to responsibly interpret laboratory reports, integrate biomarker findings into multidisciplinary tumor board discussions, and communicate these complex concepts effectively to patients and colleagues. Whether you are an oncologist, pathologist, genetic counselor, or healthcare professional looking to stay at the forefront of cancer care, this course will equip you with the knowledge to leverage molecular data for improved patient outcomes. Join us to unlock the potential of precision medicine and transform your approach to personalized cancer therapy.

Tumor Mutational Profiling and Biomarkers in Personalized Cancer Therapy

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The landscape of oncology has undergone a profound transformation with the advent of precision medicine, shifting the paradigm from broad-spectrum treatments to highly targeted, individualized therapeutic strategies. At the core of this evolution is tumor mutational profiling, a critical diagnostic approach that leverages tumor-specific molecular information to guide clinical decision-making. By analyzing the unique genomic landscape of a malignancy, clinicians can identify specific predictive, prognostic, diagnostic, and pharmacodynamic biomarkers that directly inform treatment selection. This course provides a comprehensive examination of these molecular signatures, establishing a firm foundation in the distinction between somatic alterations and inherited germline variants. It further explores the diverse specimen types and sophisticated testing methodologies utilized in modern pathology, ranging from immunohistochemistry and polymerase chain reaction-based testing to advanced next-generation sequencing.</p>

<p>Building upon these foundational principles, the curriculum systematically delves into the biological mechanisms and clinical implications of key genomic biomarkers: microsatellite instability (MSI), mismatch repair deficiency (dMMR), tumor mutational burden (TMB), and homologous recombination deficiency (HRD). Participants will explore how functional deficiencies in DNA repair pathways generate measurable genomic consequences that can predict tumor immunogenicity or sensitivity to targeted agents, such as PARP inhibitors and immune checkpoint inhibitors. Furthermore, the course emphasizes the critical importance of integrating these biomarker findings within the broader clinical context. By evaluating specimen quality, assay limitations, and patient-specific factors, healthcare professionals will be equipped to responsibly interpret complex laboratory reports and collaborate effectively within multidisciplinary tumor boards to optimize personalized cancer therapy.</p>
        </div>
    </div>
</div>
